Can stopping migraines before they start become reality?

NCT ID NCT07310290

Recruiting now Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This study is testing whether taking the migraine medication ubrogepant during the early warning phase (called prodrome) can prevent moderate or severe headaches from developing. About 189 adults in the US who already use ubrogepant will be observed for 13 weeks as they take their medication according to their normal routine. The goal is to see if treating migraines at the very first signs is more effective.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chicago Headache Center & Research Inst /ID# 272345
RECRUITING

Naperville, Illinois, 60563, United States
Neurology and Pain Specialty Center /ID# 278508
RECRUITING

Aliso Viejo, California, 92656, United States
Tri City Research Center, LLC /ID# 278800
RECRUITING

Grand Island, Nebraska, 68803, United States

Conditions

Explore the condition pages connected to this study.

MIGRAINE